Inquiry Question 1: How does technology contribute to scientific research and how do scientific advancements enhance technology?
Investigate how scientific knowledge has led to the development of a vaccine or therapeutic, including the contribution of Australian researchers
A focused answer to the HSC Investigating Science Module 6 dot point on the HPV vaccine. Covers the Frazer and Zhou virus-like particle, the National Immunisation Program rollout, the cervical cancer impact, and worked HSC past exam questions.
Have a quick question? Jump to the Q&A page
What this dot point is asking
NESA wants you to use the HPV vaccine as a case study of Australian biomedical research, link the underlying science to the vaccine technology and assess the population-health impact. The HPV vaccine is one of the most successful public health interventions of the 21st century and a frequently examined Australian case study.
The answer
The HPV vaccine, developed from foundational research by Ian Frazer and Jian Zhou at the University of Queensland in 1991, has transformed cervical cancer prevention worldwide. Australia is on track to become the first country to eliminate cervical cancer.
The cancer-virus link
Cervical cancer is the fourth most common cancer in women globally. By the 1980s it was known that nearly all cervical cancers were associated with infection by certain types of human papillomavirus (HPV), a discovery for which Harald zur Hausen received the 2008 Nobel Prize in Medicine.
HPV types 16 and 18 cause approximately 70 per cent of cervical cancers. Types 6 and 11 cause genital warts. HPV is sexually transmitted and persists in the cervix for years before progressing through low-grade and high-grade pre-cancer to invasive cancer.
Why a vaccine was hard
The standard methods for producing vaccines were not available for HPV.
- Inactivated vaccines (rabies, polio Salk) require growing large quantities of the virus, then killing it.
- Live attenuated vaccines (MMR, polio Sabin) require culturing weakened virus.
- Subunit vaccines require extracting a specific viral protein.
The problem: HPV cannot be grown in conventional cell culture. The virus replicates only in differentiating epithelial cells in intact tissue, which cannot be replicated in vitro at industrial scale. Without bulk virus, none of the established methods work.
The virus-like particle breakthrough
In 1991 at the University of Queensland's Diamantina Institute, Ian Frazer and his postdoctoral fellow Jian Zhou had a key insight. The HPV outer shell (capsid) is made of just two proteins, L1 and L2. They used recombinant DNA techniques to insert the L1 gene into yeast cells. The yeast produced large quantities of L1 protein, which spontaneously self-assembled into hollow virus-like particles (VLPs).
VLPs look like real HPV viruses on the outside but contain no viral DNA. They cannot infect cells and cannot cause disease, but they trigger a strong immune response producing antibodies against the HPV surface. When real HPV is later encountered, the antibodies neutralise it before infection.
This was published in Virology in 1991 and the patent was filed in 1992.
Commercial development
Merck and Co. licensed the patent in the late 1990s. After clinical trials demonstrating over 95 per cent protection against types 16 and 18, Gardasil (quadrivalent, against types 6, 11, 16, 18) was approved by the US FDA in June 2006. GlaxoSmithKline's Cervarix (bivalent, against types 16 and 18) followed in 2007. CSL was the Australian manufacturing partner for Gardasil.
In 2014 Merck launched Gardasil 9, protecting against nine HPV types and around 90 per cent of cervical cancers.
Australian rollout
Australia was the first country to fund free HPV vaccination at population scale.
- 2007. Free quadrivalent Gardasil for girls aged 12 to 13 via the school-based National Immunisation Program. A catch-up program for women up to 26 ran for two years.
- 2013. Extended to boys aged 12 to 13 (the world-first male vaccination program).
- 2018. Switched to Gardasil 9.
- 2023. Shifted from a 3-dose to a 1-dose schedule following WHO advice based on emerging evidence of single-dose efficacy.
Coverage exceeds 80 per cent in 15-year-old girls and boys.
Population health impact
Quantified outcomes in Australia (2007 to 2025):
- Cervical pre-cancer (high-grade lesions) in women under 20: fell from 0.8 per cent in 2005 to 0.2 per cent by 2015.
- Cervical pre-cancer in women aged 20 to 24: fell by 50 per cent.
- Genital warts in heterosexual men and women under 21: fell over 90 per cent.
- HPV 16 and 18 prevalence in vaccinated cohorts: fell from 22 per cent to under 3 per cent.
Modelling predicts cervical cancer elimination (incidence below 4 per 100,000) by 2028 to 2035, making Australia the first country to reach this milestone.
Awards and recognition
- Ian Frazer named Australian of the Year.
- Jian Zhou (posthumously, died 1999) and Ian Frazer awarded the Australia Prize.
- European Inventor Award.
Global context
WHO's Global Strategy to eliminate cervical cancer (2020) sets a 90 per cent vaccination coverage target by age 15. Lower- and middle-income countries lag in coverage, often due to vaccine cost and supply, which is being addressed by Gavi and the WHO.
Past exam questions, worked
Real questions from past NESA papers on this dot point, with our answer explainer.
2023 HSC5 marksOutline the development of the HPV vaccine and assess its impact on public health in Australia.Show worked answer →
A 5-mark answer needs the science, the people, the rollout and an explicit assessment.
- The science
- Human papillomavirus (HPV) is sexually transmitted and causes nearly all cervical cancers. By the 1990s, types 16 and 18 were known to cause around 70 per cent of cases. The challenge: HPV cannot be grown in cell culture, so traditional vaccine methods do not work.
- The breakthrough
- In 1991 at the University of Queensland, Ian Frazer and Jian Zhou produced virus-like particles (VLPs) by self-assembling the HPV outer-shell L1 protein in yeast. VLPs are non-infectious but trigger strong immune responses against real HPV.
- The vaccine
- Merck and CSL developed Gardasil (quadrivalent vaccine against types 6, 11, 16 and 18) approved by the FDA in 2006. GlaxoSmithKline developed Cervarix.
- Australian rollout
- In 2007 Australia became the first country to fund free HPV vaccination for girls aged 12 to 13 via the National Immunisation Program. Extended to boys in 2013. Coverage exceeds 80 per cent.
- Impact
- Cervical pre-cancer rates in young Australian women fell from 0.8 per cent in 2005 to 0.2 per cent by 2015. Genital warts rates fell over 90 per cent in young people. Australia is on track to eliminate cervical cancer by 2035, the first country to achieve this.
- Assessment
- Most successful vaccination program of the 21st century to date in Australia, with both technological innovation and equitable population-wide delivery. Markers reward science, named researchers, named rollout and quantified impact.
2024 HSC4 marksExplain why the HPV vaccine could not have been developed using traditional vaccine production methods.Show worked answer →
A 4-mark answer needs the traditional methods, the HPV-specific obstacles and the breakthrough solution.
- Traditional vaccine methods
- Most vaccines use either live attenuated virus (MMR, polio Sabin), inactivated virus (rabies, polio Salk), or subunit antigens (hepatitis B). These methods require growing the virus in cell culture or chicken eggs in large quantities.
- HPV obstacles
- Human papillomavirus cannot be grown in cell culture. The virus replicates only in differentiating skin or mucosal cells in living tissue, which cannot be reproduced in standard laboratory cultures. Without bulk virus, traditional vaccine manufacture is impossible.
- The breakthrough
- In 1991 Ian Frazer and Jian Zhou used recombinant DNA to express the HPV outer-shell protein L1 in yeast. When the L1 protein self-assembled into a hollow sphere (a virus-like particle, or VLP), it looked like real HPV to the immune system but contained no viral DNA and could not infect cells.
- Why it worked
- The VLP triggered an antibody response against the HPV surface protein. When real HPV is encountered, the antibodies neutralise it before infection.
Markers reward the limitation of traditional methods, the recombinant DNA breakthrough and the immunogenic-but-safe nature of VLPs.
Related dot points
- Investigate how the development of a technology, for example wireless networking, has affected society and changed scientific practice
A focused answer to the HSC Investigating Science Module 6 dot point on Australian technology. The CSIRO Wi-Fi (802.11) development story, the John O'Sullivan team, the patent enforcement that returned over a billion dollars to Australian research, and worked HSC past exam questions.
- Investigate how scientific knowledge has led to the development of a technology, including a medical implant or assistive device
A focused answer to the HSC Investigating Science Module 6 dot point on the cochlear implant. Covers Graeme Clark's multi-channel implant, the underlying neuroscience, the global commercial success, and worked HSC past exam questions.
- Communicate scientific understanding using suitable language and terminology, including the role of peer review and replication in confirming scientific findings
A focused answer to the HSC Investigating Science Module 5 dot point on peer review and replication. Covers what peer review does, why it matters, the reproducibility crisis, and worked HSC past exam questions on confirming scientific findings.